• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Niagen® improves mobility in PAD per Phase II study.

    BUSINESSWIRE

    A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

    BUSINESSWIRE

    Thorne Research, Inc. Loses Patent Challenge Decision

    BUSINESSWIRE

    ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study

    BUSINESSWIRE

    ChromaDex Announces Results of New Pilot Clinical Trial of NR Supplementation

    BUSINESSWIRE

    ChromaDex and Designs for Health Partner for New Product Development on Niagen

    BUSINESSWIRE

    ChromaDex Shares PC Research Findings and Scientific Initiations from CERP

    BUSINESSWIRE

    New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell

    PRESSRELEASE

    Taysha Partners with Invitae to Enable Rapid Access to Genetic Testing

    BUSINESSWIRE

    ChromaDex Launches Tru Niagen® Pro 500,Patented Nicotinamide Riboside

    GLOBENEWSWIRE

    New Study Demonstrates a Unique Role of Nicotinamide Riboside

    BIOSPACE

    Tru Niagen (Nicotinamide riboside) : ChromaDex vs. Elysium Health

    PATENT LITIGATION

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.